Abstract
Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies. However, for most cancers, clinical utility is limited. CTLs continuously exposed to viral or tumor antigens, with long-term expansion, may become exhausted. Exploiting fully rejuvenated iPSC-derived antigen-specific CTLs would be a powerful approach.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
